SEARCH:   Advanced

Blood, 1 June 2007, Vol. 109, No. 11, pp. 4739-4741. Prepublished online as a Blood First Edition Paper on February 27, 2007; DOI 10.1182/blood-2006-11-057968. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-11-057968v1 109/11/4739    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jenkins, J. M. Articles by Erickson-Miller, C. L. Search for Related Content PubMed PubMed Citation Articles by Jenkins, J. M. Articles by Erickson-Miller, C. L. Related Collections Hematopoiesis and Stem Cells Hemostasis, Thrombosis, and Vascular Biology Free Research Articles Brief Reports Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMATOPOIESIS Brief Report Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist Julian M. Jenkins1, Daphne Williams1, Yanli Deng1, Joanne Uhl1, Valerie Kitchen1, David Collins1, and Connie L. Erickson-Miller1 1 GlaxoSmithKline, Collegeville, PA Eltrombopag (SB-497 115) is a first-in-class, oral, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR), being developed as a treatment for thrombocytopenia of various etiologies. In this phase 1 placebo-controlled clinical trial in 73 healthy male subjects, eltrombopag was administered as once-daily oral capsules for 10 days at doses of 5, 10, 25, 30, 50, and 75 mg. The pharmacokinetics of eltrombopag were dose dependent and linear, and eltrombopag increased platelet counts in a dose-dependent manner. There were no apparent differences in the incidence or severity of adverse events in subjects receiving active or placebo study medication. These observations indicate that eltrombopag is a once-daily, oral TpoR agonist with demonstrated thrombopoietic activity in human subjects, encouraging further studies in patients with thrombocytopenia. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Pumping out platelets Douglas B. Cines Blood 2007 109: 4591-4592. [Full Text] [PDF] This article has been cited by other articles: J. B. Bussel, D. J. Kuter, V. Pullarkat, R. M. Lyons, M. Guo, and J. L. Nichol Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP Blood, March 5, 2009; 113(10): 2161 - 2171. [Abstract] [Full Text] [PDF] C. L. Erickson-Miller, E. Delorme, S.-S. Tian, C. B. Hopson, A. J. Landis, E. I. Valoret, T. S. Sellers, J. Rosen, S. G. Miller, J. I. Luengo, et al. Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist Stem Cells, February 1, 2009; 27(2): 424 - 430. [Abstract] [Full Text] [PDF] T. Gernsheimer Chronic Idiopathic Thrombocytopenic Purpura: Mechanisms of Pathogenesis Oncologist, January 1, 2009; 14(1): 12 - 21. [Abstract] [Full Text] [PDF] W. Nogami, H. Yoshida, K. Koizumi, H. Yamada, K. Abe, A. Arimura, N. Yamane, K. Takahashi, A. Yamane, A. Oda, et al. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis Haematologica, October 1, 2008; 93(10): 1495 - 1504. [Abstract] [Full Text] [PDF] K. Kaushansky Historical review: megakaryopoiesis and thrombopoiesis Blood, February 1, 2008; 111(3): 981 - 986. [Abstract] [Full Text] [PDF] J. G. McHutchison, G. Dusheiko, M. L. Shiffman, M. Rodriguez-Torres, S. Sigal, M. Bourliere, T. Berg, S. C. Gordon, F. M. Campbell, D. Theodore, et al. Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C N. Engl. J. Med., November 29, 2007; 357(22): 2227 - 2236. [Abstract] [Full Text] [PDF] J. B. Bussel, G. Cheng, M. N. Saleh, B. Psaila, L. Kovaleva, B. Meddeb, J. Kloczko, H. Hassani, B. Mayer, N. L. Stone, et al. Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura N. Engl. J. Med., November 29, 2007; 357(22): 2237 - 2247. [Abstract] [Full Text] [PDF] T. G. DeLoughery Update in Hematology Ann Intern Med, November 20, 2007; 147(10): 717 - 724. [Full Text] [PDF] Stimulating Platelet Production Journal Watch Oncology and Hematology, June 25, 2007; 2007(625): 1 - 1. [Full Text] B. Andemariam, B. Psaila, and J. B. Bussel Novel Thrombopoietic Agents Hematology, January 1, 2007; 2007(1): 106 - 113. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020